-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 RFNg3FfDCZRB5cj4CwBm6O952Z92KuMw8T9iLBsdhOReuCrSu7L9WHv1TlOXdmZL
 Hwfh5GzXR/spv9mM0vp1dg==

<SEC-DOCUMENT>0001104659-03-014248.txt : 20030708
<SEC-HEADER>0001104659-03-014248.hdr.sgml : 20030708
<ACCEPTANCE-DATETIME>20030708144104
ACCESSION NUMBER:		0001104659-03-014248
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20030630
FILED AS OF DATE:		20030708

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SAVIENT PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0000722104
		STANDARD INDUSTRIAL CLASSIFICATION:	MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833]
		IRS NUMBER:				133033811
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		ONE TOWER CENTER
		CITY:			EAST BRUNSWICK
		STATE:			NJ
		ZIP:			08816
		BUSINESS PHONE:		7324189300

	MAIL ADDRESS:	
		STREET 1:		ONE TOWER CENTER
		CITY:			EAST BRUNSWICK
		STATE:			NJ
		ZIP:			08816

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIO TECHNOLOGY GENERAL CORP
		DATE OF NAME CHANGE:	19920703

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			WATTLETON FAYE
		CENTRAL INDEX KEY:			0001014156
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-15313
		FILM NUMBER:		03778399

	BUSINESS ADDRESS:	
		STREET 1:		25 WEST 43RD STREET
		STREET 2:		SUITE 1014
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10036
		BUSINESS PHONE:		212 391 7718

	MAIL ADDRESS:	
		STREET 1:		767 FIFTH AVENUE
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10153
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>j2777_4.xml
<DESCRIPTION>4
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8" standalone="no"?>
<ownershipDocument>
    <schemaVersion>X0101</schemaVersion>

    <documentType>4</documentType>
  <periodOfReport>2003-06-30</periodOfReport>
  <notSubjectToSection16>0</notSubjectToSection16>
    <issuer>
        <issuerCik>0000722104</issuerCik>
        <issuerName>SAVIENT PHARMACEUTICALS INC</issuerName>
        <issuerTradingSymbol>SVNT</issuerTradingSymbol>
  </issuer>
  <reportingOwner>
    <reportingOwnerId>
            <rptOwnerCik>0001014156</rptOwnerCik>
            <rptOwnerName>WATTLETON FAYE</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>  </rptOwnerStreet1>
            <rptOwnerStreet2>  </rptOwnerStreet2>
            <rptOwnerCity>  </rptOwnerCity>
            <rptOwnerState>  </rptOwnerState>
            <rptOwnerZipCode>  </rptOwnerZipCode>
        </reportingOwnerAddress>
            <reportingOwnerRelationship>
      <isDirector>1</isDirector>
      <isOfficer>0</isOfficer>
      <isTenPercentOwner>0</isTenPercentOwner>
      <isOther>0</isOther>
    </reportingOwnerRelationship>
  </reportingOwner>
  <nonDerivativeSecurity>
    <securityTitle>
      <value>Common Stock, $.01 par value per share</value>
    </securityTitle>
    <transactionDate>
      <value>2003-06-30</value>
    </transactionDate>
    <transactionCoding>
      <transactionFormType>4</transactionFormType>
      <transactionCode>A</transactionCode>
      <equitySwapInvolved>0</equitySwapInvolved>
    </transactionCoding>
    <transactionTimeliness>
      <value/>
    </transactionTimeliness>
    <transactionAmounts>
      <transactionShares>
        <value>535</value>
        <footnoteId id="F1"/>
      </transactionShares>
      <transactionValue>
        <value>4.67</value>
      </transactionValue>
      <transactionAcquiredDisposedCode>
        <value>A</value>
      </transactionAcquiredDisposedCode>
    </transactionAmounts>
    <postTransactionAmounts>
      <sharesOwnedFollowingTransaction>
        <value>6219</value>
      </sharesOwnedFollowingTransaction>
    </postTransactionAmounts>
    <ownershipNature>
      <directOrIndirectOwnership>
        <value>D</value>
      </directOrIndirectOwnership>
    </ownershipNature>
  </nonDerivativeSecurity>
  <derivativeSecurity>
    <securityTitle>
      <value>Options to purchase Common Stock, $.01 par value per share</value>
    </securityTitle>
    <conversionOrExercisePrice>
      <value>4.67</value>
    </conversionOrExercisePrice>
    <transactionDate>
      <value>2003-06-30</value>
    </transactionDate>
    <transactionCoding>
      <transactionFormType>4</transactionFormType>
      <transactionCode>A</transactionCode>
      <equitySwapInvolved>0</equitySwapInvolved>
    </transactionCoding>
    <transactionTimeliness>
      <value/>
    </transactionTimeliness>
    <transactionAmounts>
      <transactionShares>
        <value>5000</value>
      </transactionShares>
      <transactionValue>
        <value>0</value>
      </transactionValue>
      <transactionAcquiredDisposedCode>
        <value>A</value>
      </transactionAcquiredDisposedCode>
    </transactionAmounts>
    <exerciseDate>
      <value>2004-06-30</value>
    </exerciseDate>
    <expirationDate>
      <value>2013-06-30</value>
    </expirationDate>
    <underlyingSecurity>
      <underlyingSecurityTitle>
        <value>Common Stock, $.01 par value per share</value>
      </underlyingSecurityTitle>
      <underlyingSecurityShares>
        <value>5000</value>
      </underlyingSecurityShares>
    </underlyingSecurity>
    <postTransactionAmounts>
      <sharesOwnedFollowingTransaction>
        <value>5000</value>
      </sharesOwnedFollowingTransaction>
    </postTransactionAmounts>
    <ownershipNature>
      <directOrIndirectOwnership>
        <value>D</value>
      </directOrIndirectOwnership>
    </ownershipNature>
  </derivativeSecurity>
  <footnotes>
    <footnote id="F1">These shares were granted pursuant to the Company's Stock Compensation Plan for Outside Directors, which provides for the grant to non-employee directors of that number of shares of Common Stock having an aggregate fair market value on the last business day of each quarter equal to $2,500, until she is no longer an Outside Director. On June 30, 2003, the fair market value of the Common Stock, based on the closing price, was $4.67.
</footnote>
  </footnotes>
  <ownerSignature>
    <signatureName>/s/ Faye Wattleton</signatureName>
    <signatureDate>2003-07-02</signatureDate>
  </ownerSignature>
</ownershipDocument>

</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----